<DOC>
	<DOCNO>NCT02268864</DOCNO>
	<brief_summary>The purpose study determine efficacy 12- 24-week treatment regimen simeprevir combination daclatasvir , measure sustain virologic response 12 ( SVR12 ) , treatment-naive , chronic hepatitis C virus ( HCV ) genotype 1b-infected participant advance fibrosis compensate cirrhosis ( METAVIR F3/F4 ) .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Combination Simeprevir Daclatasvir Chronic Hepatitis C Genotype 1b-Infected Participants</brief_title>
	<detailed_description>This open-label ( people know treatment participant receive ) study investigate efficacy , safety tolerability simeprevir daclatasvir chronic Hepatitis ( inflammation liver ) C virus ( HCV ) genotype 1b infected participant treatment-naive . The total study duration participant approximately 40 week approximately 52 week . The study consist 4 part : Screening Phase ( approximately 4 week ) open-label treatment Phase ( 12 week ) , optional open label treatment phase extension ( 12 Weeks ) follow-up Phase ( Week 40 Week 52 ) . Participants receive simeprevir ( 150 milligram [ mg ] capsule ) daclatasvir ( 60 mg tablet ) orally daily 12 24 week . Efficacy primarily evaluate percentage participant SVR12 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Participant must chronic Hepatitis C virus ( HCV ) genotype 1b infection confirm Screening Participant must HCV ribonucleic acid ( RNA ) great ( &gt; ) 10,000 international unit per milliliter ( IU/mL ) Screening Participant must document fibrosis stage Screening ( Screening Day 1 [ baseline ] ) . Liver disease stag base one follow method . ) Shear wave elastography ( Fibroscan ) within less equal ( &lt; = ) 6 month Screening Screening Day 1 ( baseline ) . METAVIR F3 &gt; 9.6 Kilopascals ( kPa ) cutoff cirrhosis great equal ( &gt; = ) 14.6 kPa . b ) A biopsy document METAVIR F3F4 . Biopsy perform within 24 month Screening accept participant METAVIR score F3 . For cirrhotic participant ( METAVIR score F4 ) biopsy perform previous time acceptable Participants cirrhosis must hepatic imaging procedure ( ultrasound , compute tomography [ CT ] scan magnetic resonance image [ MRI ] ) within 6 month prior Screening visit ( Screening Day 1 ) finding suspicious hepatocellular carcinoma Participant must body mass index ( BMI ) &gt; = 18 Kilogram per meter^2 ( kg/m^2 ) Participant must treatment naive ( , receive prior treatment HCV approve investigational drug ) Participant coinfection HCV another genotype ; ) Participant HCV genotype 1b coinfection HCV genotype genotype 1b Chronic HCV genotype 1binfected participant presence genetic variant cod NS5AY93H and/or L31M/V amino acid substitution Screening Participant evidence current previous episode hepatic decompensation ( include control uncontrolled ascites , bleed varix hepatic encephalopathy ) Participant chronic liver disease nonHCV etiology ( include limit hemochromatosis , Wilson 's disease , alfa 1antitrypsin deficiency , cholangitis , drug alcoholrelated liver disease , primary biliary cirrhosis ) Participant uncontrolled clinically significant disease clinically significant finding Screening opinion investigator could compromise participant ' safety could interfere participant participate complete study Participant coinfection hepatitis A hepatitis B virus ( hepatitis A antibody immunoglobulin M [ IgM ] hepatitis B surface antigen [ HBsAg ] positive Screening ) Participant receive solid organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatitis C Chronic</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>Daclatasvir</keyword>
</DOC>